Braveheart Bio, Inc.
BRVE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BRVE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BRVE
Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused solely on developing BHB-1893, a myosin inhibitor for hypertrophic cardiomyopathy (HCM), with no approved products or revenue to date.
Key risk: Single product candidate risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 1 clinical trial · 1 catalyst for Braveheart Bio, Inc..
Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused solely on developing BHB-1893, a myosin inhibitor for hypertrophic cardiomyopathy (HCM), with no approved products or revenue to date.
- Braveheart Bio is a clinical-stage company with no approved products and no revenue from product sales [sec · filed 2026-07-15].
- The company's sole product candidate is BHB-1893, a myosin inhibitor for hypertrophic cardiomyopathy (HCM), licensed from Hengrui [sec · filed 2026-07-15].
- As of March 31, 2026, the company had $80.6 million in cash and cash equivalents [sec · filed 2026-07-15].
- Net losses were $14.3 million for the three months ended March 31, 2026, and $66.1 million for the year ended December 31, 2025 [sec · filed 2026-07-15].
- Accumulated deficit was $80.3 million as of March 31, 2026 [sec · filed 2026-07-15].
What works
- BHB-1893 has undergone significant clinical development by Hengrui, including a dose-ranging Phase 2 study in symptomatic obstructive HCM and an ongoing Phase 3 study in oHCM in China [sec · filed 2026-07-15].
- The company holds exclusive rights to Hengrui's library of additional myosin-binding compounds, providing potential pipeline expansion beyond BHB-1893 [sec · filed 2026-07-15].
What to weigh
- Braveheart Bio has incurred operating losses since inception and expects to continue incurring significant losses for the foreseeable future, with an accumulated deficit of $80.3 million as of March 31, 2026 [sec · filed 2026-07-15].
- The company is entirely dependent on the success of a single product candidate, BHB-1893, for HCM, and has not completed development of any product candidate to date [sec · filed 2026-07-15].
- BHB-1893 may fail to demonstrate sufficient efficacy or safety, or may not differentiate from existing HCM therapies, which would materially harm the business [sec · filed 2026-07-15].
- The company will need substantial additional funding to continue operations, and if unable to raise capital, may have to delay or reduce development efforts [sec · filed 2026-07-15].
From the filings
Quoted directly from source documents.
The company has no approved products and no revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC filings · July 15, 2026
BHB-1893 is the sole product candidate, and the company is dependent on its success.
“we are focused on a single indication, HCM, and we are substantially dependent on the success of our only product candidate, BHB-1893”
SEC filings · July 15, 2026
Cash position as of March 31, 2026.
“As of March 31, 2026, we had $80.6 million in cash and cash equivalents.”
SEC filings · July 15, 2026
Net losses and accumulated deficit.
“Our net losses were $14.3 million and $66.1 million for the three months ended March 31, 2026 and for the year ended December 31, 2025, respectively. We had an accumulated deficit of $80.3 million as of March 31, 2026.”
SEC filings · July 15, 2026
Catalyst timeline
- 2028-11-01 · Phase3_Topline — Topline results from a Phase 3, multi-region, randomized, double-blind, active-comparator-controlled trial of BHB-1893 in HCM.
Risks & what to watch (4)›
Key risks
- Single product candidate risk — Entire pipeline depends on BHB-1893 for HCM; failure would materially harm the business [sec · filed 2026-07-15].
- History of operating losses — Incurred losses since inception in 2024; expects continued losses and may never achieve profitability [sec · filed 2026-07-15].
- Substantial additional funding needed — Existing cash may not be sufficient; may need to delay or reduce development if unable to raise capital [sec · filed 2026-07-15].
- Clinical and regulatory uncertainty — BHB-1893 may fail to show efficacy or safety needed for approval; development is time-consuming and expensive [sec · filed 2026-07-15].
What to watch
- Initiation and progress of the LIONHEART-H Phase 3 trial for BHB-1893 in oHCM [sec · filed 2026-07-15].
- Results from Hengrui's ongoing Phase 2 trial of HRS-1893 in HFpEF, which may inform BHB-1893's potential [sec · filed 2026-07-15].
- Cash runway and any future capital raises, given $80.6 million as of March 31, 2026 and ongoing losses [sec · filed 2026-07-15].
- Regulatory milestones and potential approval decisions for BHB-1893 in China and the U.S. [sec · filed 2026-07-15].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Braveheart Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Braveheart Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
Financial health data unavailable
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~794d
13 buys · 0 sells (180d)
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Braveheart Bio, Inc.?
Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused solely on developing BHB-1893, a myosin inhibitor for hypertrophic cardiomyopathy (HCM), with no approved products or revenue to date.
What is Braveheart Bio, Inc.'s next catalyst?
Braveheart Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Active-Comparator-Controlled Trial " — expected November 1, 2028.
Who is the CEO of Braveheart Bio, Inc.?
Dr. Travis Murdoch B.S., M.D., M.Sc. is the chief executive officer of Braveheart Bio, Inc. (BRVE).
Where is Braveheart Bio, Inc. headquartered?
Braveheart Bio, Inc. (BRVE) is headquartered in San Francisco, CA, United States.
What therapeutic areas does Braveheart Bio, Inc. focus on?
Braveheart Bio, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.